Cannabidiol (CBD) in the Therapeutics Industry
Drug Enforcement and Policy Center, No. 10, August 2019
9 Pages Posted: 20 Aug 2019
Date Written: August 19, 2019
Use of Cannabidiol (CBD) in the therapeutics industry has become increasingly popular in the last few years. CBD rode into public consciousness on the coattails of three booming consumer trends: the herbal supplement industry, the anxiety economy, and the growing legitimate cannabis industry. However, many uncertainties remain about the legality, safety, and quality of CBD. The passage of the 2018 Farm Bill legalized hemp production throughout the US, thereby removing hemp-derived CBD from Center for Disease Control and Prevention (CDC)-regulation. However, the U.S. Food and Drug Administration (FDA) still stakes a claim on regulating dietary supplements and food additives containing CBD. The sudden legality of CBD, coupled with uncertainty as to its safety, quality, and effectiveness, means it is imperative for states to support research and impose sufficient regulatory oversight over CBD-infused products.
Keywords: CBD, hemp, cannabidiol, regulation, FDA, oversight
Suggested Citation: Suggested Citation